Roivant Sciences LTD Form 4 insider transactions

Roivant Sciences' President & Immunovant CEO, Eric Venker, exercised stock options and subsequently sold 200,000 common shares for a significant gain.

Roivant Sciences Director Melissa B. Epperly sold 41,861 common shares for a weighted average price of $28.68.

Roivant Sciences Ltd. CFO Richard Pulik reported a routine disposition of 1,000 common shares for tax withholding related to RSU vesting.

Roivant Sciences' President and Immunovant CEO, Eric Venker, disposed of 7,051 common shares at $27.15 each to cover tax withholding obligations related to RSU vesting.

Roivant Sciences President and Vant Chair Frank Torti sold 3 million common shares for over $81 million after exercising stock options, completing a pre-arranged trading plan.

A director of Roivant Sciences Ltd. reported the sale of over 1.2 million common shares through a pre-arranged trading plan.

Daniel Allen Gold, a Director and 10% owner of Roivant Sciences Ltd., reported the sale of over 1.2 million common shares through pre-arranged transactions.

QVT Financial LP, a 10% owner and director by deputization, reported selling 1,225,784 common shares of Roivant Sciences Ltd. for approximately $32.6 million through a pre-arranged trading plan.

Roivant Sciences Ltd. President and CIO Mayukh Sukhatme exercised stock options and subsequently sold common shares, adjusting his beneficial ownership.

Roivant Sciences Director James C. Momtazee reported an acquisition of 609 common shares as a compensation award and a disposition of 122 shares for tax withholding, resulting in a net beneficial ownership of 109,030 shares.

Roivant Sciences Director Ilan Oren reported the acquisition of 1,164 common shares and the disposition of 124 shares for tax purposes, resulting in a net beneficial ownership of 119,428 shares.

Roivant Sciences Ltd. Director Melissa Epperly increased her direct beneficial ownership through a share award, partially offset by a tax-related disposition.

Roivant Sciences Ltd. President and Immunovant CEO Eric Venker sold 200,000 common shares for a weighted average price of $21.92 after exercising stock options at $3.85.

Roivant Sciences' President and CIO, Mayukh Sukhatme, exercised expiring stock options and subsequently sold a portion of the acquired common shares in late December 2025.

Roivant Sciences President Frank Torti reported an acquisition of shares from a subsidiary exchange, followed by sales for tax obligations and a charitable donation.

Roivant Sciences CFO Richard Pulik exercised stock options and subsequently sold a portion of his common shares on December 23, 2025.

Eric Venker, President and Immunovant CEO of Roivant Sciences Ltd., exercised stock options and subsequently sold a portion of the acquired common shares to cover applicable withholding taxes and exercise costs.

Roivant Sciences CFO Richard Pulik disposed of 2,129 common shares to cover tax withholding obligations related to RSU vesting, as per a pre-planned transaction.

Roivant Sciences' President and CIO, Mayukh Sukhatme, exercised stock options and subsequently sold a portion of the acquired common shares.

A director of Roivant Sciences Ltd. reported multiple sales of common shares totaling over 1.6 million shares in mid-December 2025.

Roivant Sciences Ltd. director Keith S. Manchester reported indirect sales of over 1.69 million common shares by QVT Financial Investment Cayman Ltd. in December 2025, executed under a Rule 10b5-1 plan.

QVT Financial LP, a 10% owner and director by deputization, reported multiple sales of Roivant Sciences Ltd. common shares totaling over 1.6 million shares.

Roivant Sciences CEO Matthew Gline exercised stock options and subsequently sold or net-settled an equivalent number of shares, including disgorging profits as per SEC regulations.

Vivek Ramaswamy, a 10% owner and director of Roivant Sciences Ltd., exercised stock options and subsequently sold a portion of the acquired shares, while also using net settlement for others, across multiple transactions in December 2025.

Roivant Sciences Ltd. reported a significant acquisition of Immunovant, Inc. common stock, increasing its beneficial ownership to over 113 million shares.

Roivant Sciences Ltd.'s President and Immunovant CEO, Eric Venker, exercised stock options and subsequently sold 200,000 common shares under a pre-arranged 10b5-1 trading plan.

Roivant Sciences CFO Richard Pulik disposed of 1,235 common shares at $20.27 each to cover tax withholding related to RSU vesting.

Roivant Sciences' President & Immunovant CEO, Eric Venker, reported a net settlement of 7,051 common shares for tax withholding related to RSU vesting.

Roivant Sciences Director Keith Manchester reported the sale of 1.3 million common shares totaling over $26.3 million through an indirect holding.

Roivant Sciences Ltd. Director Daniel Allen Gold, also a 10% owner, reported the sale of 1.3 million common shares for approximately $26.3 million on November 19, 2025.